Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension | Zendy

George L. Bakris | Zendy; Vivian Fonseca | Zendy; Richard E. Katholi | Zendy; Janet B. McGill | Zendy; Franz H. Messerli | Zendy; Robert A. Phillips | Zendy; Philip Raskin | Zendy; Jackson T. Wright | Zendy; R. Oakes | Zendy; Mary Ann Lukas | Zendy; Karen M. Anderson | Zendy; David S.H. Bell | Zendy; for the GEMINI Investigators | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension

Author(s) -

George L. Bakris,

Vivian Fonseca,

Richard E. Katholi,

Janet B. McGill,

Franz H. Messerli,

Robert A. Phillips,

Philip Raskin,

Jackson T. Wright,

R. Oakes,

Mary Ann Lukas,

Karen M. Anderson,

David S.H. Bell,

for the GEMINI Investigators

Publication year - 2004

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.292.18.2227

Subject(s) - medicine , carvedilol , metoprolol , glycemic , microalbuminuria , metoprolol tartrate , diabetes mellitus , type 2 diabetes mellitus , glycated hemoglobin , hydrochlorothiazide , blood pressure , randomized controlled trial , endocrinology , type 2 diabetes , cardiology , heart failure

Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however, some components of the metabolic syndrome are worsened by some beta-blockers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research